### Comment:
He says that other pharma companies have better drugs in the pipeline. 
  
 Just find out if that's true or not.

### REPLY:
The analyst was vouching for ACST, which is a tiny company, with a krill oil based product in development. There is no way they can avoid a multi-year CVOT trial if they want to compete with Vascepa. If ACST's P3 trial is successful, they'll get a label covering &gt;500mg TG level patients. Vascepa's upcoming label will be 20-times bigger.

### END.